Senolytic Patents Research (14)
14 papers in the Senolytic Patents topic, indexed by PF-Atlas from PubMed and global journals.
- Exercise-induced Right-to-left Shunt in a Patient with Combined Pulmonary Fibrosis and Emphysema · Internal Medicine · 2025
- A Case of Immune Checkpoint Inhibitor-Induced Probable Myocarditis and Treatment Response · Cureus · 2023
- BDS.MDS.FELLOW IN CRANIO-MAXILLOFACIAL SURGERY SENIOR LECTURER DEPARTEMENT OF ORAL AND MAXILLOFACIAL SURGERY MANIPAL COLLEGE OF DENTAL SCIENCES · Patent/IP · 2022
- Novel Galectin-3 Inhibitors for Treating Fibrosis. · ACS medicinal chemistry letters · 2021
- Novel Benzimidazole Derivatives as Transient Receptor Potential Channel 6 Inhibitors. · ACS medicinal chemistry letters · 2021
- Novel Pyridazines as Autotaxin Inhibitors for Treating Inflammatory Airway or Fibrotic Diseases. · ACS medicinal chemistry letters · 2021
- POS0861 EFFECTIVENESS AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS: A PROPENSITY SCORE CONTROL MATCHED OBSERVATIONAL STUDY OF THE EUSTAR COHORT · Annals of the Rheumatic Diseases · 2021
- A Concise Overview on Recent Advances in Pharmaceutical Aerosols and Their Commercial Applications · Current Materials Science · 2021
- AB0553 THE NOCEBO PHENOMENON PARTLY ACCOUNTS FOR DIARRHOEA AMONG PARTICIPANTS IN THE RANDOMIZED PLACEBO-CONTROLLED TRIAL OF NINTEDANIB FOR INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS · Annals of the Rheumatic Diseases · 2020
- SAT0313 CORRELATION BETWEEN PROGRESSION OF SKIN FIBROSIS AND PROGRESSION OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SSC-ILD: DATA FROM THE SENSCIS TRIAL · Annals of the Rheumatic Diseases · 2020
- OP0115 EFFECT OF NINTEDANIB ON PROGRESSION OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH AUTOIMMUNE DISEASE-RELATED ILDS: FURTHER DATA FROM THE INBUILD TRIAL · Annals of the Rheumatic Diseases · 2020
- SAT0333 SERUM METABOLITES AS BIOMARKERS IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE · Annals of the Rheumatic Diseases · 2020
- THU0330 EFFECTS OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED ILD AND DIFFERING EXTENTS OF SKIN FIBROSIS: FURTHER ANALYSES OF THE SENSCIS TRIAL · Annals of the Rheumatic Diseases · 2020
- Nanopharma 2017- Overcoming Biological Barriers In Severe Lung Diseases Through Tailored Inhalable Nanoparticles - Francesca Ungaro, University of Napoli Federico II · Pharmaceutical bioprocessing · 2020
Medical disclaimer. Research listings are for information only and are not medical advice.